Clinical article · Acute care, Specialties, Pathways and documents

When to suspect acute porphyria, and other treatable rare diseases not to miss

Written for
Hospital physicians, emergency doctors and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Consider acute porphyria in severe, unexplained abdominal pain with a soft abdomen and normal imaging, especially in young women and with hyponatraemia, neuropathy or confusion.
  • The screening test is a spot urine porphobilinogen, protected from light and sent while the patient has symptoms; total urinary porphyrins are not a substitute.
  • Treatment starts with removing triggers, checking every medicine against a porphyria drug-safety database, and intravenous haem therapy for significant attacks.
  • Givosiran reduced attack rates in a randomised trial and is an option for recurrent attacks under specialist care.
  • Wilson disease, hereditary angioedema and Fabry disease are other rare conditions where a missed diagnosis means a missed treatment.
  • Before settling on a rare diagnosis, make sure an atypical common disease or a drug effect has been excluded.

Why acute porphyria is missed

The acute hepatic porphyrias are inherited disorders of haem synthesis: acute intermittent porphyria, variegate porphyria, hereditary coproporphyria and the very rare porphyria due to severe aminolaevulinic acid dehydratase deficiency [1, 5, 6]. Acute intermittent porphyria is the most common, with symptomatic disease estimated at about 1 in 100,000, and attacks occur mainly in women of childbearing age [1]. Most gene carriers never have an attack, because penetrance is low [4].

The presentation is non-specific and there is no pathognomonic sign [3]. The typical attack is severe, generalised abdominal pain without peritoneal signs or abnormalities on cross-sectional imaging [1], which is easily labelled as functional pain or drug-seeking. Variegate porphyria and hereditary coproporphyria can also cause blistering of sun-exposed skin.

Features that should prompt a urine test

  • Severe abdominal pain out of proportion to the examination, with normal imaging [1]
  • Vomiting, constipation, tachycardia and hypertension during the attack [4]
  • Hyponatraemia, which may be severe [4]
  • Peripheral neuropathy, predominantly motor, sometimes progressing to paralysis [4]
  • Seizures, confusion, anxiety or other psychiatric features [4, 5]
  • Red or dark urine, or urine that darkens on standing
  • A trigger: a new medicine, alcohol, fasting or dieting, the luteal phase, infection or stress [4]
  • A relative with porphyria, or previous unexplained attacks

Some drugs commonly used for pain, nausea or seizures can precipitate or worsen an attack. Until porphyria has been excluded in a patient who fits this picture, check each new medicine against a porphyria drug-safety database.

Making the diagnosis

  1. Send a spot urine sample for porphobilinogen, with creatinine, protected from light and collected while the patient is symptomatic [4].
  2. Ask the laboratory how quickly the result can be reported; if the test is sent away, discuss the case with a porphyria specialist or reference laboratory the same day.
  3. A substantially raised porphobilinogen in a compatible clinical picture establishes an acute porphyria attack [1].
  4. Identify the type with urinary aminolaevulinic acid, urine and faecal porphyrins and a plasma fluorescence scan, then confirm with genetic testing, which also allows testing of relatives [1, 2].

Total urinary porphyrins are raised in many other conditions, including liver disease, and are not a substitute for porphobilinogen. A normal porphobilinogen during a typical attack makes the common acute porphyrias unlikely, but a sample taken long after the attack, or after haem therapy, can be misleading.

Treating an attack

  1. Stop any precipitating medicines and review every prescribed drug for porphyria safety.
  2. Give adequate analgesia and antiemetics chosen from drugs considered safe in porphyria, and treat infection if present.
  3. Give intravenous haem therapy (hemin or haem arginate) for an attack that needs admission, as recommended by expert guidance [1, 2]; carbohydrate loading alone is reserved for mild attacks or while haem is awaited.
  4. Monitor sodium, blood pressure and heart rate, muscle power and respiratory function, because weakness can progress to respiratory failure.
  5. Arrange specialist follow-up, advice on triggers and testing of relatives.

For patients with recurrent attacks, givosiran, a small interfering RNA that suppresses hepatic aminolaevulinic acid synthase 1, was compared with placebo in the ENVISION trial [7] and reduced attacks and other disease manifestations [8]. Its use, and long-term monitoring for chronic complications, should be planned with a specialist porphyria service [2].

The availability of haem preparations and givosiran differs between countries, including within India. Identify the nearest supply and specialist advice early rather than during an attack.

Other treatable rare diseases not to miss

ConditionCluesFirst testsWhy it matters
Wilson diseaseUnexplained liver disease in a young person, neurological or psychiatric change, haemolysisCaeruloplasmin, 24-hour urinary copper, slit-lamp examination; no single test confirms or excludes it [9]Diagnostic delay is common, and treatment needs specialist supervision because neurological symptoms can worsen at first [9]
Hereditary angioedemaRecurrent swelling without urticaria, abdominal attacks with vomiting, family history [11]C4, then C1 inhibitor level and function [10]Attacks do not respond to antihistamines, corticosteroids or adrenaline, but specific treatments exist [10]
Fabry diseaseBurning pain in the hands and feet, angiokeratomas, proteinuria, unexplained left ventricular hypertrophyAlpha-galactosidase A activity in men; GLA gene testing in women, whose enzyme activity can be normalUp to 1% of patients diagnosed with hypertrophic cardiomyopathy have Fabry disease, which has disease-specific therapy [12]
Metabolic myopathiesRecurrent rhabdomyolysis with exercise or fasting, an affected siblingCK and acylcarnitine profile during an episode, then a gene panelAvoiding the trigger prevents further kidney injury

Thinking about rare disease without overdiagnosing it

  • Rule out the familiar first: an unusual form of a common disease, a medicine's side effect, or two ordinary conditions occurring together.
  • Notice patterns that point to a group of disorders, such as problems spanning several organ systems, attacks brought on by fasting or intercurrent illness, an unexpectedly young age at onset, or no response to usual treatment.
  • Put treatable conditions at the top of the differential and test for them first.
  • Treat a genetic variant of uncertain significance as unresolved, not as a diagnosis, and involve clinical genetics.

How Sana Health helps

Rare Disease and Genetics starts by asking whether a common condition, a drug or two diseases together explain the picture. It then restates the findings as a phenotype, builds a candidate list with treatable conditions such as acute porphyria, Wilson disease and hereditary angioedema placed first, and shows for each the features that fit, those that do not and the confirmatory test. Testing is proposed in tiers, genetic results are read in ACMG/AMP terms, and the report notes counselling, relatives and referral, with verified references.

Questions

What is the first test for suspected acute porphyria?

A spot urine porphobilinogen, ideally with creatinine, protected from light and collected while the patient has symptoms. A substantially raised level in a compatible picture establishes an acute attack; the type is then defined by further biochemical and genetic tests.

Can acute porphyria present with hyponatraemia and seizures?

Yes. Severe attacks can be complicated by hyponatraemia, seizures, psychiatric symptoms and a motor neuropathy, usually alongside severe abdominal pain. Anticonvulsants and other drugs should be checked for porphyria safety before they are given.

Which rare diseases should a physician consider because they are treatable?

Examples include the acute porphyrias, Wilson disease, hereditary angioedema, Fabry disease and several metabolic myopathies and inborn errors of metabolism. In each, recognising the pattern and sending the right first test changes treatment.

References